Zentalis Pharmaceuticals
ZNTL
ZNTL
120 hedge funds and large institutions have $1.24B invested in Zentalis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
23% less capital invested
Capital invested by funds: $1.61B → $1.24B (-$371M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
Holders
120
Holding in Top 10
3
Calls
$17.1M
Puts
$536K
Top Buyers
| 1 | +$56.8M | |
| 2 | +$26M | |
| 3 | +$23.1M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.8M |
| 5 |
Morgan Stanley
New York
|
+$10.2M |
Top Sellers
| 1 | -$42.1M | |
| 2 | -$28M | |
| 3 | -$24.3M | |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$17M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14M |